1-10 of 10
Type 1 Diabetes TrialNet Study Group
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Comparative Analysis of the Sensitivity, Specificity, Concordance, and the 5-year Predictive Power of Diabetes-related Autoantibody Assays

Available to Purchase
Jeffrey P. Krischer, PhD, Sarah Muller, BS, Lu You, PhD, Peter Achenbach, MD, Elena Bazzigaluppi, BSc, Cristina Brigatti, BSc, Vito Lampasona, MD, Anu Mathew, PhD, Peter Robinson, PhD, David Seftel, MD, George Sigal, PhD, Cheng-ting Tsai, PhD, Mingyue Wang, MD, Liping Yu, MD, Type 1 Diabetes TrialNet Study Group
Journal: Diabetes
Diabetes db240814
https://doi.org/10.2337/db24-0814
Published: 10 March 2025
View articletitled, A Comparative Analysis of the Sensitivity, Specificity, Concordance, and the 5-year Predictive Power of Diabetes-related Autoantibody Assays
Open the PDF for A Comparative Analysis of the Sensitivity, Specificity, Concordance, and the 5-year Predictive Power of Diabetes-related Autoantibody Assays in another window
Journal Articles

Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

Free
Emily K. Sims, Rachel E.J. Besser, Colin Dayan, Cristy Geno Rasmussen, Carla Greenbaum, Kurt J. Griffin, William Hagopian, Mikael Knip, Anna E. Long, Frank Martin, Chantal Mathieu, Marian Rewers, Andrea K. Steck, John M. Wentworth, Stephen S. Rich, Olga Kordonouri, Anette-Gabriele Ziegler, Kevan C. Herold, for the NIDDK Type 1 Diabetes TrialNet Study Group
Journal: Diabetes
Diabetes 2022;71(4):610–623
https://doi.org/10.2337/dbi20-0054
Published: 22 March 2022
View articletitled, Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective
Open the PDF for Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective in another window
Meeting Abstracts

110-OR: Type 2 Diabetes (T2D)–Associated TCF7L2 Genetic Variants and Indices of Insulin Secretion and Sensitivity in Individuals at Risk for Type 1 Diabetes (T1D)

Free
MARIA J. REDONDO, MEGAN V. WARNOCK, LAURA E. BOCCHINO, SUSAN GEYER, ALBERTO PUGLIESE, ANDREA STECK, INGRID LIBMAN, CARMELLA EVANS-MOLINA, DOROTHY J. BECKER, JAY SOSENKO, FIDA BACHA, TYPE 1 DIABETES TRIALNET STUDY GROUP
Journal: Diabetes
Diabetes 2020;69(Supplement_1):110-OR
https://doi.org/10.2337/db20-110-OR
Published: 01 June 2020
View articletitled, 110-OR: Type 2 Diabetes (T2D)–Associated TCF7L2 Genetic Variants and Indices of Insulin Secretion and Sensitivity in Individuals at Risk for Type 1 Diabetes (T1D)
Journal Articles

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression

Free
Tania Habib, S. Alice Long, Peter L. Samuels, Archana Brahmandam, Megan Tatum, Andrew Funk, Anne M. Hocking, Karen Cerosaletti, Michael T. Mason, Elizabeth Whalen, David J. Rawlings, Carla Greenbaum, Jane H. Buckner, the Type 1 Diabetes TrialNet Study Group
Journal: Diabetes
Diabetes 2019;68(6):1240–1250
https://doi.org/10.2337/db18-1081
Published: 20 March 2019
View articletitled, Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression
Open the PDF for Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression in another window
Includes: Supplementary data
Meeting Abstracts

Index60 Is More Strongly Associated with the Highest Type 1 Diabetes (T1D) Risk HLA DR3-DQ2/DR4-DQ8 (DQ2/DQ8) Genotype than Glucose Measures

Free
MARIA J. REDONDO, SUSAN GEYER, HEBA M. ISMAIL, KEVAN C. HEROLD, ALBERTO PUGLIESE, JERRY P. PALMER, JAY SOSENKO, TYPE 1 DIABETES TRIALNET STUDY GROUP
Journal: Diabetes
Diabetes 2018;67(Supplement_1):205-LB
https://doi.org/10.2337/db18-205-LB
Published: 01 July 2018
View articletitled, Index60 Is More Strongly Associated with the Highest Type 1 Diabetes (T1D) Risk HLA DR3-DQ2/DR4-DQ8 (DQ2/DQ8) Genotype than Glucose Measures
Meeting Abstracts

Individuals with Single Islet Autoantibody Positivity (SA+) at Type 1 Diabetes (T1D) Diagnosis Have Distinct Characteristics

Free
MARIA J. REDONDO, JAY SOSENKO, INGRID LIBMAN, JENNIFER J. MCVEAN, MARK A. ATKINSON, DOROTHY J. BECKER, SUSAN GEYER, THE TYPE 1 DIABETES TRIALNET STUDY GROUP
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1691-P
https://doi.org/10.2337/db18-1691-P
Published: 01 July 2018
View articletitled, Individuals with Single Islet Autoantibody Positivity (SA+) at Type 1 Diabetes (T1D) Diagnosis Have Distinct Characteristics
Journal Articles

HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression

Free
Alberto Pugliese, David Boulware, Liping Yu, Sunanda Babu, Andrea K. Steck, Dorothy Becker, Henry Rodriguez, Linda DiMeglio, Carmella Evans-Molina, Leonard C. Harrison, Desmond Schatz, Jerry P. Palmer, Carla Greenbaum, George S. Eisenbarth, Jay M. Sosenko, the Type 1 Diabetes TrialNet Study Group
Journal: Diabetes
Diabetes 2016;65(4):1109–1119
https://doi.org/10.2337/db15-1105
Published: 28 January 2016
View articletitled, HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression
Open the PDF for HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression in another window
Includes: Supplementary data
Journal Articles

Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies

Free
Craig A. Beam, Stephen E. Gitelman, Jerry P. Palmer, the Type 1 Diabetes TrialNet Study Group
Journal: Diabetes
Diabetes 2014;63(9):3120–3127
https://doi.org/10.2337/db14-0095
Published: 16 August 2014
View articletitled, Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies
Open the PDF for Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies in another window
Includes: Supplementary data
Journal Articles

Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073

Open Access
Carla J. Greenbaum, Craig A. Beam, on behalf of the Type 1 Diabetes TrialNet Study Group
Journal: Diabetes
Diabetes 2013;62(6):e8
https://doi.org/10.2337/db13-0115
Published: 17 May 2013
View articletitled, Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073
Open the PDF for Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073 in another window
Journal Articles

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

Open Access
Carla J. Greenbaum, Craig A. Beam, David Boulware, Stephen E. Gitelman, Peter A. Gottlieb, Kevan C. Herold, John M. Lachin, Paula McGee, Jerry P. Palmer, Mark D. Pescovitz, Heidi Krause-Steinrauf, Jay S. Skyler, Jay M. Sosenko, on behalf of the Type 1 Diabetes TrialNet Study Group
Journal: Diabetes
Diabetes 2012;61(8):2066–2073
https://doi.org/10.2337/db11-1538
Published: 17 July 2012
View articletitled, Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
Open the PDF for Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data in another window
Includes: Supplementary data